Drug Utilization of Tranexamic Acid in the Department of Surgery

Abstract

Synthetic lysine derivative tranexamic acid reversibly blocks plasminogen lysine binding sites, hence inhibiting fibrinolysis. In order to halt bleeding, antifibrinolytics encourage blood coagulation. During surgery, tranexamic acid dramatically lowers blood loss. The study's objective was to ascertain how often tranexamic acid was used in the surgery department. The study used observational methods. The study was carried out at Rajajinagar, Bengaluru's ESIC MC-PGIMSR. 28 participants (88%) in the trial received TXA after surgery, 3 (9%), during surgery, and 1 (3%), both during and after surgery. seventeen (53%) belonged to the 25–34 age range, seven (22%) to the 35–44 age range, and eight (25%) to the 18–24 age range. There were 13 (41%) females and 19 (59%) males. 23 individuals (72%) received 500 mg, 9 subjects received 1g, 29 subjects (91%) received BD (bis in die), 2 subjects (6%) received STAT, and 1 subject (3%) received SOS in this study. Of the 32 participants, 22 (69%) had an infection of the gastrointestinal system, 3 (9%) had endocrine disease, 3 (9%) had cancer, 3 (9%) underwent surgery for diabetic foot problems, and 1 (3%) had soft tissue damage. Of the thirty-two individuals, twenty-four (75%) spent six to ten days in the hospital, four (13%) stayed one to five days, three (9%) stayed eleven to fifteen days, and one (3%) stayed for the maximum duration of sixteen to twenty days. Concluding that TXA was given to most patients after surgery, it may be assumed that most blood loss happens after surgery. TXA was not given to any of the research participants during surgery. This study demonstrates the requirement for an antifibrinolytic TXA in cases where post-operative bleeding continues.